Mechanism of Action
Endothelial Gene Expression Regulation
The Lys-Glu-Asp sequence adopts a conformation permitting direct interaction with histone H2A-H2B complexes at promoter regions in vascular endothelial cells. This activates transcription of eNOS (endothelial nitric oxide synthase), prostacyclin synthase, and vascular protective transcription factors. In aged endothelium, where eNOS expression and NO bioavailability are characteristically reduced, Vesugen's chromatin-activating effect restores a more youthful transcriptional signature. The result is improved vasodilation, reduced platelet aggregation, and decreased monocyte adhesion, the three key endothelial functions compromised in early atherogenesis.
Anti-inflammatory Vascular Effects
Vesugen reduces NF-kB activation in vascular smooth muscle and endothelial cells, decreasing expression of ICAM-1, VCAM-1, and E-selectin, the adhesion molecules that promote monocyte entry into the vessel wall. This anti-inflammatory vascular effect complements the eNOS-mediated vasodilatory action. In aged rodent models, Vesugen treatment reduces intimal thickening and normalizes vascular reactive oxygen species (ROS) levels, consistent with protection against age-related vascular remodeling.
Research Summary
Vascular Aging Studies
EmergingKhavinson's group published data showing Vesugen normalizes vascular endothelial gene expression in aged mice toward a younger pattern, including restored eNOS and reduced inflammatory marker expression. Functional vascular studies showed improved endothelium-dependent vasodilation in aged animal aortic ring preparations after Vesugen treatment. Human data is limited to observational clinical reports from Russian cardiovascular medicine practices.
Longevity Protocol Contribution
EmergingIn multi-peptide Khavinson longevity protocols including Vesugen alongside Epithalon and Thymalin, cardiovascular mortality was reduced compared to controls in aging cohort studies. Isolating Vesugen's specific contribution within combination protocols is methodologically difficult; the vascular endpoint improvements (blood pressure normalization, reduced intima-media thickness progression) in treated groups are consistent with its proposed mechanism.
Calculate your Vesugen dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Vascular longevity | 5-10 mcg/day SC | 10 days; 1-2x/year | Subcutaneous |
| Intranasal vascular support | 5 mcg/day | 10 days | Intranasal |
| Combination Khavinson protocol | 5 mcg/day | 10 days concurrent | Subcutaneous alongside Epithalon, Thymalin |
Vesugen is a microdose peptide, the effective range is 1-10 mcg/day, not milligrams. Dose it similarly to Vilon and other Khavinson dipeptide/tripeptide bioregulators.
Interactions
Safety Profile
Vesugen's tripeptide structure and microgram dosing carry an inherently minimal toxicity profile. No serious adverse events have been documented in Russian clinical experience over decades of use. Local SC injection reactions (mild redness, temporary tenderness) are occasionally noted. No carcinogenicity, organ toxicity, or reproductive effects have been reported in animal studies. As an endothelial-activating agent, theoretical caution applies in conditions where vasodilation is contraindicated (severe hypotension, recent ischemic stroke). Not WADA prohibited. Not FDA approved. Not scheduled.
References
- [1]Khavinson VKh et al. "Tissue-specific short peptides as geroprotectors and inductors of chromatin gene activity." Adv Gerontol. 2014;27(1):16-24.
- [2]Khavinson VKh, Linkova NS. "Mechanism of peptide regulation of genome." Bull Exp Biol Med. 2010;150(1):10-13.